EVFM — Evofem Biosciences, Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1618835 ·
Last close
$0.00
Market Cap
$569.9K
52W High
$0.01
52W Low
$0.00
ADV30
162,759
Next earnings
—
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 2,633,000 2,122,000 -2,489,000 -11,036,000 7,522,000 — 95,038,000
Mar 2026 899,000 489,000 -4,569,000 -5,465,000 7,442,000 1,491,000 85,072,000
Dec 2025 9,561,000 6,969,000 3,345,000 2,788,000 20,274,000 — 94,610,000
Sep 2025 4,952,000 4,047,000 -982,000 -1,569,000 13,807,000 0 88,873,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-472,000
Investing CF
$-5,000
Financing CF
$14,000
CapEx
$-5,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.14
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-914,019,000
Inventory
$2,155,000
Receivables
$2,685,000
ST Investments
—
EBIT TTM
$-4,695,000
Pretax Income TTM
$-15,288,000
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$18,045,000
EBITDA
$-4,420,000
Free Cash Flow
$6,408,750
Enterprise Value
$60,227,480
Total Cash
$144,000
Total Debt
$54,325,000
Shares Out
132,530,081
Trailing EPS
$-0.11
Book Value
$-0.66
ROE
—
ROA
-26.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 20,183,000 1,439,000 391,000 20,274,000 94,610,000 -74,336,000 -1,992,000
Dec 2024 19,363,000 -7,676,000 -8,860,000 23,789,000 95,046,000 -71,257,000 -3,885,000
Dec 2023 18,218,000 -17,847,000 52,979,000 10,600,000 77,100,000 -66,510,000 -8,968,000
Dec 2022 16,837,000 -84,124,000 -76,698,000 25,200,000 96,963,000 -71,800,000 -70,410,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$7,522,000
Forward EPS
$-0.55

Peers — same industry

TickerNameMarket CapLastDaily %
BIOM BIOMOLECULAR LIFE HOLDINGS, INC. $580.8K $0.50 —
LABT Lakewood-Amedex Biotherapeutics Inc. $508.3K $0.21 —
VBIO Valion Bio, Inc. $482.3K $0.54 —
CYTOF Altamira Therapeutics Ltd. $405.8K $0.07 —
PTIX Protagenic Therapeutics, Inc.\new $814.6K $0.45 —

News headlines (Yahoo Finance, 1h cache)

Quarterly Profit Could Change The Case For Evofem Biosciences Stock
2026-11-18 08:10 · Yahoo
HUB Cyber Security Expands Into Women’s Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet Turnaround
2026-07-01 11:00 · Yahoo
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
2025-11-21 14:25 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.